Commentary: European medicines agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 372-373

  Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MENINGOCOCCUS VACCINE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; BACTERIAL STRAIN; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MEMBRANE; MENINGOCOCCOSIS; NONHUMAN; NOTE; OUTER MEMBRANE; PATHOGENESIS; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; SERUM BACTERICIDAL ANTIBODY ASSAY;

CHILD, PRESCHOOL; DRUG APPROVAL; EUROPE; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINATION;

EID: 84876297636     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318282942f     Document Type: Note

References (25)

1. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816-1820.
2. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103: 10834-10839.
3. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789-799.
4. Welsch JA, Moe GR, Rossi R, et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis. 2003;188:1730-1740.
5. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107:3770-3775.
6. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55:687-698.
7. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-1573.
8. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227.
9. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177:501-510.
10. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-1137.
11. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-e79.
12. Gossger N, Snape MD, Yu LM, et al.; European MenB Vaccine Study Group. Immunogenic ity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-582.
13. McNicholas A, Galloway Y, Stehr-Green P, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin. 2007;3:196-204.
14. Nøkleby H, Aavitsland P, O'Hallahan J, et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25:3080-3084.
15. Colin AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307:614-615.
16. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51-B63.
17. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134:556-566.
18. Wang X, Colin A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739-4744.
19. Colin AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-191.
20. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(suppl 2):S54-S65.
21. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107:19490-19495.
22. Pajon R, Beernink PT, Harrison LH, et al. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010;28: 2122-2129.
23. Vogel U, Taha MK, Findlow H, et al. Strain coverage of a multicomponent meningococcal vaccine (4cMenB) in Western Europe. In: XVIIIth International Pathogenic Neisseria Conference. Wurzburg, Germany; 2012
24. Kim E, Paulos S, Carlone G, et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. In: Frosch M, Rudel T, Vogel U, eds. XVIIIth International Pathogenic Neisserial Conference. Wurzburg, Germany; 2012.
25. Ibarz-Pavón AB, Maclennan J, Andrews NJ, et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis. 2011;204:1046-1053.